InflaRx N.V. IFRX
1.17 USD -0.07 (-5.65%)
At closeNov 13, 2026, 4:20 PM EST
1.14 -0.03 -2.56%
After hours · Nov 13, 4:20 PM ET
1.15 Day range 1.24
0.798 52-week range 2.95
- YTD
- +15.84%
- 1 year
- -7.87%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million. Instinct Bio Technical Co…
zacks.com Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now InflaRx (IFRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall…
zacks.com Down 20.3% in 4 Weeks, Here's Why You Should You Buy the Dip in InflaRx (IFRX) The heavy selling pressure might have exhausted for InflaRx (IFRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts…
defenseworld.net Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX) Travere Therapeutics (NASDAQ: TVTX - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
benzinga.com InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses…
globenewswire.com InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
seekingalpha.com InflaRx N.V. (IFRX) Analyst/Investor Day Transcript InflaRx N.V. ( IFRX ) Analyst/Investor Day November 3, 2026 8:00 AM EST Company Participants Jan Medina - Head of Investor Relations & VP Niels Riedemann - Co-Founder, CEO & Executive Director Thomas…
marketbeat.com InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials InflaRx NASDAQ: IFRX outlined plans to advance its oral C5a receptor antagonist izicopan in ANCA-associated vasculitis (AAV), with an initial focus on patients with kidney involvement and a parallel…
benzinga.com InflaRx Q3 EPS $(0.02) Beats $(0.07) Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 90.48 percent increase over losses of $(0.21) per…
globenewswire.com InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in…
globenewswire.com InflaRx Announces November Investor Events Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
globenewswire.com InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026 Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
defenseworld.net InflaRx N.V. (NASDAQ:IFRX) Stock Has Average Target Price of $7.43 Shares of InflaRx N.V. (NASDAQ: IFRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are covering the firm, MarketBeat reports. One…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
globenewswire.com InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
globenewswire.com InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
globenewswire.com InflaRx to Host Virtual Capital Markets Day Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.
benzinga.com This GE Vernova Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday Analysts initiate: Sell GEV ($470); Buy IFRX ($8), LYNX ($21); Overweight FRSH ($18); Outperform NPWR ($2.75).
benzinga.com Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8 Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $8.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
globenewswire.com InflaRx Announces Participation in September Investor Conferences Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
benzinga.com Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6 Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
benzinga.com InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per…
globenewswire.com InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for…
globenewswire.com InflaRx to Report Second Quarter 2026 Results on August 6, 2026 Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
defenseworld.net Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA) Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses…- benzinga.com InflaRx Mulls Feasibility For AAV In Europe InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening…
globenewswire.com InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…- benzinga.com Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9 Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.
- benzinga.com HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8 HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.
- benzinga.com Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4 Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
seekingalpha.com InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
marketbeat.com InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.The Company intends to…- benzinga.com InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com InflaRx Regains Nasdaq Compliance InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written…
- benzinga.com 10 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com InflaRx Announces New In Vitro Findings Demonstrating That Izicopan Does Not Exhibit Time-Dependent Inhibition Of CYP3A4, Indicator For Risk For Ddis And Liver Toxicity InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan…- benzinga.com InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab…
- benzinga.com Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14 Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.
- benzinga.com InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 88.89 percent decrease over losses of $(0.09) per…
benzinga.com Earnings Scheduled For March 19, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com InflaRx Presents Oral Presentation At 2026 American Academy Of Dermatology Annual Meeting InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking…
- benzinga.com InflaRx Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the…
benzinga.com InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session